Compare DQ & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DQ | OMER |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 844.6M |
| IPO Year | 2010 | 2008 |
| Metric | DQ | OMER |
|---|---|---|
| Price | $12.31 | $21.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.91 | ★ $32.50 |
| AVG Volume (30 Days) | 782.6K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $69.82 | N/A |
| Revenue Next Year | $34.34 | $233.22 |
| P/E Ratio | ★ N/A | $24.01 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.17 | $4.06 |
| 52 Week High | $36.59 | $19.65 |
| Indicator | DQ | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 66.21 |
| Support Level | $11.47 | $18.00 |
| Resistance Level | $12.55 | N/A |
| Average True Range (ATR) | 0.43 | 0.83 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 42.19 | 86.14 |
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.